FDA Approves Adrabetadex for Infantile Onset NPC

FDA approved intrathecal adrabetadex (Lembaz) for patients with Niemann–Pick disease type C whose neurological symptoms began before age six and who weigh at least 7 kg. FDA described a 55% lower death risk versus…




